Oxalyl chloride → HCID 178418553, Verbindung

1.56 g of oxalyl chloride are added at -5° to 0° C. to 39 ml of chloroform containing 0.99 ml of dimethylformamide, and the mixture is stirred at the same temperature for 15 minutes. A solution of 4.23 g of (Z)-2-(2-tritylaminothiazol-4-yl)-2-[(2-pyrrolidon-3-yl)oxyimino]acetic acid (d-isomer) and 0.84 g of triethylamine in 39 ml of chloroform is added to said mixture at -30° C. The mixture is stirred at the same temperature for 5 minutes. Then, a solution of 7β-amino-3-(1-pyridiniomethyl)-3-cephem-4-carboxylate in chloroform (said solution is prepared by suspending 5.0 g of the dihydrochloride of said cephem compound in 39 ml of chloroform and adding 11 ml of N,O-bis(trimethylsilyl)acetamide thereto to dissolve said salt therein) is added to the said mixture at -30° to -10° C. After the mixture is stirred at the same temperature for 30 minutes, said mixture is concentrated to dryness under reduced pressure. 100 ml of 80% aqueous formic acid are added to the residue, and said aqueous mixture is stirred at room temperature for one hour. 100 ml of water are added to the mixture, and insoluble materials are filtered off. The filtrate is washed with ethyl acetate and is concentrated to dryness under reduced pressure. The residue thus obtained is dissolved in water and chromatographed on a column of non-ionic polymer resin Diaion HP-20 (resistered trade mark, manufactured by Mitsubishi Chemical Industries Ltd., Japan). The column is washed with water, followed by elution with 20% aqueous methanol. The fractions containing the cephalosporin compound are collected and concentrated to dryness under reduced pressure. Acetone is added to the residue, and the resulting powder is collected by filtration. 2.14 g of 7β-{(Z)-2-(2-aminothiazol-4-yl)-2-[(2-pyrrolidon-3-yl)oxyimino]acetamido}-3-(1-pyridiniomethyl)-3-cephem-4-carboxylate (d-isomer) are obtained. Another designation of this dextrorotatory isomer is shown as 7β-{(Z)-2-(2-aminothiazol-4-yl)-2-[((3R)-2-pyrrolidon-3-yl)oxyimino]acetamido}-3-(1-pyridiniomethyl)-3-cephem-4-carboxylate.

1. customat -30° C
2. stirringThe mixture is stirred at the same temperature for 5 minutes
3. customis prepared
4. dissolutionto dissolve
5. addition) is added to the said mixture at -30° to -10° C
6. stirringAfter the mixture is stirred at the same temperature for 30 minutes
7. concentrationis concentrated to dryness under reduced pressure
8. addition100 ml of 80% aqueous formic acid are added to the residue
9. stirringis stirred at room temperature for one hour
10. addition100 ml of water are added to the mixture, and insoluble materials
11. filtrationare filtered off
12. washThe filtrate is washed with ethyl acetate
13. concentrationis concentrated to dryness under reduced pressure
14. customThe residue thus obtained
15. customchromatographed on a column of non-ionic polymer resin Diaion
16. washThe column is washed with water
17. washfollowed by elution with 20% aqueous methanol
18. additionThe fractions containing the cephalosporin compound
19. customare collected
20. concentrationconcentrated to dryness under reduced pressure
21. additionAcetone is added to the residue
22. filtrationthe resulting powder is collected by filtration

ORD-Eintrag

ord-bf05a855f14647528c0f0fc05e736fca

Quelldatensatz

uspto-grants-1988_02

DOI

10.6084/m9.figshare.5104873.v1

Patentnummer

US04727071